NasdaqGM:SUPNPharmaceuticals
Supernus Pharmaceuticals Record Revenues And New CNS Drugs Prompt Valuation Questions
Supernus Pharmaceuticals reported record revenues in 2025.
The company completed the integration of Sage Therapeutics.
New products ONAPGO for Parkinson's disease and ZURZUVAE for postpartum depression were launched.
The business expanded into new therapeutic areas despite supply constraints.
For investors looking at NasdaqGM:SUPN, these company updates come with a stock that last closed at $54.73 and has returned 70.7% over the past year. Over 3 years the stock is up 37.5%, and over 5...